BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:
This Act shall be known and may be cited as "The Honorable Jimmy Carter Cancer Treatment Access Act."
WHEREAS, the Honorable Jimmy Carter of Plains, Georgia, announced in August that he had an aggressive form of melanoma skin cancer; and
WHEREAS, in that announcement, President Carter detailed that tumors had spread from his skin into his liver and brain. President Carter received surgery, radiation, and multiple doses of another drug; and
WHEREAS, on December 6, President Carter revealed that his physicians said that all signs of cancer were gone; and
WHEREAS, it is the intent of the General Assembly that every Georgian with health insurance that covers cancer should have the same access to cancer drugs as President Carter.
Chapter 24 of Title 33 of the Official Code of Georgia Annotated, relating to general insurance provisions, is amended by adding a new Code section to read as follows:
(a) As used in this Code section, the term:
(1) 'Health benefit plan' means any hospital, health, or medical expense insurance policy, hospital or medical service contract, employee welfare benefit plan, contract or agreement with a health maintenance organization, subscriber contract or agreement, preferred provider organization, accident and sickness insurance benefit plan, or other insurance contract under any other name. The term shall include any health insurance plan established under Article 1 of Chapter 18 of Title 45 and under Article 7 of Chapter 4 of Title 49, the 'Georgia Medical Assistance Act of 1977.'
(2) 'Stage four advanced, metastatic cancer' means cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other areas or parts of the body.
(b) No health benefit plan issued, delivered, or renewed in this state that, as a provision of hospital, medical, or surgical services, directly or indirectly covers the treatment of stage four advanced, metastatic cancer shall limit or exclude coverage for a drug approved by the United States Food and Drug Administration by mandating that the insured shall first be required to fail to successfully respond to a different drug or drugs or prove a history of failure of such drug or drugs; provided, however, that the use of such drug or drugs is consistent with best practices for the treatment of stage four advanced, metastatic cancer and is supported by peer reviewed medical literature."
All laws and parts of laws in conflict with this Act are repealed.